IL-10+ regulatory B lymphocytes are impacted by intradermal PBMCs therapy in patients with unexplained recurrent pregnancy loss (uRPL)
Current Research in Translational Medicine · 2026
DOI: 10.1016/j.retram.2026.103565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Research in Translational Medicine, 2026. Verfasst von Lida Aslanian-Kalkhoran und 5 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, School of Medicine, Tabriz University of M…. Hauptthemen laut MEDLINE: Interleukin-10, Abortion, Habitual, B-Lymphocytes, Regulatory, Leukocytes, Mononuclear. Die Arbeit nennt 66 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Following the confirmation of studies on the improvement of pregnancy outcomes after treatment with lymphocytes, this project aimed to assess the effectiveness of this treatment method in patients with unexplained recurrent pregnancy loss (uRPL). METHODS: After isolating B cells from 100 uRPL patients, the frequency of IL-10+B cells after treatment was measured by flow cytometry. Real-time PCR was applied to appraise the mRNA expression of microRNA and Programmed death-ligand 1(PD-L1) genes. The measurement of interleukin-10 (IL-10) secretory level in the supernatant medium was performed using the Enzyme-linked immunosorbent assay (ELISA) method. RESULTS: The data demonstrated that the frequency of IL-10+B cells increased after treatment with PBMCs. The expression levels of miR-10a and miR-155 were elevated in patients who received PBMCs treatments, while the levels of miR-16 and miR-21 were decreased. Furthermore, after PBMCs treatment, an increased expression level of PD-L1 was observed. The ELISA results indicated that IL-10 secretion levels increased significantly with PBMC therapy. In the group treated with PBMCs, 33 out of 50 women (66%) achieved a live birth, compared to only 15 out of 50 women (30%) in the control group. CONCLUSION: In patients with uRPL, PBMCs treatment can enhance the chances of successful pregnancy by positively influencing immune regulatory factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Student's Research Committee, Tabriz Un…
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
- Department of Pediatrics, School of Medicine Children Medical Research & Training Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: Aghebatil@tbzmed.ac.ir.
Zitieren
APA
Aslanian-Kalkhoran, L., Soltani-Zangbar, M. S., Aghebati-Maleki, A., Heris, J. A., Yousefi, M., & Aghebati-Maleki, L. (2026). IL-10+ regulatory B lymphocytes are impacted by intradermal PBMCs therapy in patients with unexplained recurrent pregnancy loss (uRPL). Current Research in Translational Medicine. https://doi.org/10.1016/j.retram.2026.103565
Vancouver
Aslanian-Kalkhoran L, Soltani-Zangbar MS, Aghebati-Maleki A, Heris JA, Yousefi M, Aghebati-Maleki L. IL-10+ regulatory B lymphocytes are impacted by intradermal PBMCs therapy in patients with unexplained recurrent pregnancy loss (uRPL). Current Research in Translational Medicine. 2026. doi:10.1016/j.retram.2026.103565
BibTeX
@article{AslanianKalkhoran2026,
author = {Aslanian-Kalkhoran, Lida and Soltani-Zangbar, Mohammad Sadegh and Aghebati-Maleki, Ali and Heris, Javad Ahmadian and Yousefi, Mehdi and Aghebati-Maleki, Leili},
title = {IL-10+ regulatory B lymphocytes are impacted by intradermal PBMCs therapy in patients with unexplained recurrent pregnancy loss (uRPL)},
journal = {Current Research in Translational Medicine},
year = {2026},
doi = {10.1016/j.retram.2026.103565}
}
EUVIMED